Trimetazidine for stable angina pectoris

Expert Opinion on Pharmacotherapy
H R Cross

Abstract

Stable angina pectoris, a symptom of coronary heart disease (CHD), manifests as stress-induced ischaemic episodes resulting in severe chest pain. Therapeutic aims are to improve quality of life by decreasing anginal attacks and to prevent myocardial infarction (MI) and death. Current anginal medications include beta-blockers and calcium antagonists, which decrease ischaemic severity by reducing cardiac workload, and nitrates, which increase coronary blood flow. A new therapeutic approach is the use of metabolic agents, such as trimetazidine, which are cytoprotective during ischaemia. Results of several clinical trials demonstrated that trimetazidine, at the standard dose of 20 mg t.i.d., increased exercise capacity, decreased anginal incidence and decreased left-ventricular (LV) dysfunction compared to placebo. Trimetazidine was also as effective as propranolol (120 - 160 mg/day) and nifedipine (40 mg/day) in decreasing anginal episodes and improving exercise parameters. Trimetazidine improved anginal frequency and symptoms in patients in which treatment with diltiazem, nifedipine, propranolol, pindolol, oxprenolol or long-acting nitrates had failed. Trimetazidine was also more effective than isosorbide dinitrate (30 mg/day) as...Continue Reading

References

Sep 24, 1992·The American Journal of Cardiology·U Thadani
Aug 1, 1990·Cardiovascular Drugs and Therapy·S Dalla-VoltaA Desideri
Jan 1, 1987·European Journal of Clinical Pharmacology·P SellierP Ourbak
Feb 1, 1995·British Heart Journal·M M GandhiD A Wood
Nov 1, 1995·Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine·H R CrossK Clarke
Jul 26, 1996·International Journal of Cardiology·C L PapadopoulosG C Sakadamis
Sep 16, 1998·The American Journal of Cardiology·H El BananiD Feuvray
Mar 30, 1999·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·A SettafJ P Tillement
Jul 20, 1999·Cardiovascular Drugs and Therapy·S AllibardiM Samaja
Dec 2, 2000·Cardiovascular Drugs and Therapy·D TzivoniI Kobrin
Jan 11, 2001·Journal of Cardiovascular Pharmacology and Therapeutics·D F Pauly, C J Pepine

❮ Previous
Next ❯

Citations

Jul 27, 2010·Cardiovascular Drugs and Therapy·Danny Dvir, Alexander Battler
Feb 10, 2004·Progress in Retinal and Eye Research·Neville N OsborneJosé Melena
Jun 30, 2005·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Taher El-KadySherif Abdel-Hady
Nov 11, 2003·Current Medical Research and Opinion·Mario Marzilli
Dec 4, 2014·International Journal of Cardiology·Song PengKaiyong Li
Aug 18, 2009·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Mathias Basner, Uwe Siebert
Apr 5, 2014·The Journal of Pharmacology and Experimental Therapeutics·John R UssherGary D Lopaschuk
Jul 12, 2019·Cardiology and Therapy·Naveen SeecheranDavid Schneider
Feb 22, 2017·Advances in Therapy·Maria Glezer, UNKNOWN CHOICE-2 study investigators
Mar 21, 2017·The Cochrane Database of Systematic Reviews·Agustín CiapponiJeff Harrison
Jul 15, 2021·Annals of Medicine·Yan YangShiying Shao

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.